ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting

    Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

    Colin Edgerton1, Janna Radtchenko 2 and V. Michael Holers 3, 1Articularis Healthcare, Charleston, 2Trio Health, La Jolla, CA, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
  • Abstract Number: 1139 • 2019 ACR/ARP Annual Meeting

    Lifetime Direct Medical and Indirect Cost of Knee Osteoarthritis: Impact of Pain and Structural Severity

    Elizabeth Stanley1, James Sullivan 2, Jamie Huizinga 1, Jamie Collins 3, Jeffrey Katz 4 and Elena Losina 5, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, 3Brigham and Women's Hospital and Harvard Medical School, Boston, 4Brigham and Women's Hospital/Harvard Medical School, Boston, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Symptomatic knee OA is a debilitating condition that affects 14 million adults in the US. We estimated the variability of lifetime OA-related direct and…
  • Abstract Number: 1140 • 2019 ACR/ARP Annual Meeting

    The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients

    Yufei Zheng1, Hui Xie 2, J. Antonio Avina-Zubieta 3, Kia Yazdani 4, John Esdaile 5 and Diane Lacaille 6, 1Arthritis Research Canada, Richmond, BC, Canada, 2Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, 3Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 4Arthritis Research Canada and the University of British Columbia, Richmond, 5Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, 6Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: To assess socioeconomic (SES), gender, urban-rural, and regional disparities in the risk of acute myocardial infarction (MI) among rheumatoid arthritis patients.Methods: We conducted a…
  • Abstract Number: 1141 • 2019 ACR/ARP Annual Meeting

    Racial Disparities in Lupus Medication Adherence

    Kai Sun1, Amanda Eudy 1, Jennifer Rogers 1, Lisa Criscione-Schreiber 1, Jayanth Doss 1, Rebecca Sadun 1 and Megan Clowse 1, 1Duke University, Durham

    Background/Purpose: Medication non-adherence is common among SLE patients and is disproportionately more frequent in underrepresented racial minorities. We examined adherence gaps between minority and Caucasian…
  • Abstract Number: 1142 • 2019 ACR/ARP Annual Meeting

    Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study

    Kai Sun1, Carrie Dombeck 1, Teresa Swezey 1, Amy Corneli 1, Amanda Eudy 1, Rebecca Sadun 1, Jennifer Rogers 1, Lisa Criscione-Schreiber 1, Jayanth Doss 1 and Megan Clowse 1, 1Duke University, Durham

    Background/Purpose: SLE disproportionately affects underrepresented racial minorities, groups that often have lower rates of medication adherence. This study aimed to explore barriers and facilitators of…
  • Abstract Number: 1143 • 2019 ACR/ARP Annual Meeting

    Racial Disparities in Factors Associated with SLICC Damage Score Among Patients with SLE

    Kai Sun1, Amanda Eudy 1, Jennifer Rogers 1, Lisa Criscione-Schreiber 1, Jayanth Doss 1, Rebecca Sadun 1 and Megan Clowse 1, 1Duke University, Durham

    Background/Purpose: Significant racial disparities exist in SLE outcomes. Few studies have examined modifiable factors intrinsic to physician/patient encounters that may contribute to such disparities. We…
  • Abstract Number: 1144 • 2019 ACR/ARP Annual Meeting

    Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis

    Candace Feldman1, Jessica Williams 1, Courtnie Phillip 1, Corine Sinnette 1, Karen Mancera-Cuevas 2, Patricia Canessa 3, Gina Curry 4, Maryann Mason 2 and Rosalind Ramsey-Goldman 2, 1Brigham and Women's Hospital, Boston, MA, 2Northwestern University, Chicago, IL, 3IPHA, Chicago, IL, 4University of Chicago, Chicago, IL

    Background/Purpose: Despite a disproportionate burden of lupus and poorer outcomes among individuals of African descent (hereafter “black”) compared to white individuals, black individuals are underrepresented…
  • Abstract Number: 1145 • 2019 ACR/ARP Annual Meeting

    The Representation of Skin Tones in Images of Patients with Lupus Erythematosus

    Amaad Rana1, Abbey Witt 1, Heather Jones 1, Muithi Mwanthi 1 and Lisa Zickuhr 1, 1Washington University School of Medicine, Saint Louis

    Background/Purpose: Racial disparities exist in healthcare. Research shows that the disproportionate representation of race in educational materials contributes to this disparity. Race is a known…
  • Abstract Number: 1146 • 2019 ACR/ARP Annual Meeting

    Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity

    Prathima Anandi 1, Alyson Dickson 2, Vivian Kawai 2, C. Michael Stein 2 and Cecilia Chung3, 1Vanderbilt University Medical Center, Nashville, 2Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University, Nashville, TN

    Background/Purpose: Randomized clinical trials have reported that 56-68% of patients with lupus nephritis treated with mycophenolate mofetil (MMF) respond to therapy, and a randomized clinical…
  • Abstract Number: 1147 • 2019 ACR/ARP Annual Meeting

    Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients

    Allen Anandarajah1, Caroline Thirukumaran 1, Kelly callahan 1, Jennifer Anolik 1 and Christopher Ritchlin 2, 1University of Rochester Medical Center, Rochester, NY, 2Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with a high rate of hospitalizations and is the sixth highest reason for 30-day readmissions among all medical…
  • Abstract Number: 1148 • 2019 ACR/ARP Annual Meeting

    Examining Five Year Lupus Retention in Care in an Academic Cohort

    Christie Bartels1 and Maria Schletzbaum 1, 1University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: SLE often causes silent damage, making routine clinic and lab monitoring critical for detecting new manifestations or flares. The 2012 ACR nephritis guidelines recommended…
  • Abstract Number: 1149 • 2019 ACR/ARP Annual Meeting

    Are There Country Differences in Disease Activity and Life Impact of Psoriatic Arthritis? An Analysis of 436 Patients from 14 Countries

    Laure Gossec1, Juan Cañete 2, Ana-Maria Orbai 3, Ying-Ying Leung 4, Penelope Palominos 5, Rossana Scrivo 6, Andra Balanescu 7, Emmanuelle Dernis 8, Sandra Talli 9, Adeline Ruyssen-Witrand 10, Martin SOUBRIER 11, Sibel Zehra Aydin 12, Lihi Eder 13, Inna Gaydukova 14, Laura Coates 15, Umut Kalyoncu 16, Pascal Richette 17, M. Elaine Husni 18, Maarten de Wit 19, Josef Smolen 20, Ennio Lubrano 21 and Uta Kiltz 22, 1Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 2Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, 5Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, 6Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, 7Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, 8Rheumatology Department, Le Mans Central Hospital, Le Mans, France, 9Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, 10Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, 11CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, 12University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, 13Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, 14North-western State medical university, St Petersburg, Russia, 15University of Oxford, Oxford, United Kingdom, 16Hacettepe University Department of Rheumatology, Ankara, Turkey, 17Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, 18Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 19Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, 20Medical University of Vienna, Vienna, Austria, 2115. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, 22Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany

    Background/Purpose: In psoriatic arthritis (PsA), there is a substantial life impact perceived by patients, although many treatments are now available at least in countries with…
  • Abstract Number: 1150 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Systematic Review

    Kaitlin Lima1, Courtnie Phillip 2, Jessica Williams 2, Jonna Peterson 1, Candace Feldman 3 and Rosalind Ramsey-Goldman 4, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, 4Northwestern University, Chicago, IL

    Background/Purpose: Non-white racial/ethnic groups remain underrepresented in rheumatic disease-related research despite being disproportionately affected by these disorders. We aimed to systematically review the literature regarding…
  • Abstract Number: 1151 • 2019 ACR/ARP Annual Meeting

    The Impact of Gender on Time to Rheumatoid Arthritis Classification

    Caitrin Coffey1, John Davis 1 and Cynthia Crowson 2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester

    Background/Purpose: Rheumatoid arthritis differs between genders with regard to comorbidities, extra-articular manifestations, core measures of disease activity, and treatment response.  Gender has not previously been…
  • Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting

    Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy

    JB Boone1, S. Bobo Tanner 1 and April Barnado 1, 1Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
  • « Previous Page
  • 1
  • …
  • 1014
  • 1015
  • 1016
  • 1017
  • 1018
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology